SCHEMBL7245213

SCHEMBL7245213

CNCCCS(=O)(=O)c1ccc(C(C)NCCOc2ccc(NS(C)(=O)=O)cc2)c(N)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
GRIN1 Q05586 6/20 0.41
GRIN2B Q13224 6/20 0.41
KCNH2 Q12809 2/20 0.41
LMNA P02545 1/20 0.40
MAPK1 P28482 1/20 0.40
ALDH1A1 P00352 2/20 0.35
CACNA1F O60840 1/20 0.35
CHRM2 P08172 1/20 0.35
ACHE P22303 1/20 0.35
AGTR1 P30556 1/20 0.35
DRD3 P35462 1/20 0.35
CACNA1D Q01668 1/20 0.35
CACNA1S Q13698 1/20 0.35
CACNA1C Q13936 1/20 0.35
MEN1 O00255 1/20 0.35
HTT P42858 1/20 0.35
KMT2A Q03164 1/20 0.35
LTA4H P09960 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7245207 0.77 NPC1 (0.48) NPC1RAB9AGRIN1GRIN2BKCNH2
SCHEMBL7245215 0.76 ADRB1 (0.47) NPC1RAB9AGRIN1GRIN2BKCNH2
SCHEMBL9733253 0.75 NPC1 (0.69) NPC1RAB9AGRIN1GRIN2BKCNH2
SCHEMBL7233802 0.72 NPC1 (0.51) NPC1RAB9AGRIN1GRIN2BKCNH2
SCHEMBL7237802 0.72 NPC1 (0.51) NPC1RAB9AGRIN1GRIN2BKCNH2
SCHEMBL9389817 0.71 NPC1 (0.67) NPC1RAB9AGRIN1GRIN2BKCNH2
SCHEMBL7245832 0.66 ALDH1A1 (0.48) NPC1RAB9AGRIN1GRIN2BKCNH2
SCHEMBL7245209 0.66 KCNH2 (0.51) NPC1RAB9AGRIN1GRIN2BKCNH2
SCHEMBL8795293 0.64 NPC1 (0.71) NPC1RAB9AGRIN1GRIN2BKCNH2
SCHEMBL14113144 0.64 NPC1 (0.93) NPC1RAB9AGRIN1GRIN2BKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030044845-A1 Novel therapeutic agents for membrane transporters THERAVANCE BIOPHARMA R&D IP, LLC 2003-03-06 US disclosed
WO-1999064045-A9 NOVEL THERAPEUTIC AGENTS FOR MEMBRANE TRANSPORTERS ADVANCED MEDICINE INC (US) 2001-07-05 WO disclosed
EP-1089749-A4 NOVEL THERAPEUTIC AGENTS FOR MEMBRANE TRANSPORTERS ADVANCED MEDICINE INC (US) 2001-04-11 EP disclosed
EP-1089749-A1 NOVEL THERAPEUTIC AGENTS FOR MEMBRANE TRANSPORTERS Advanced Medicine, Inc. (US) 2001-04-11 EP disclosed
WO-1999064045-A1 NOVEL THERAPEUTIC AGENTS FOR MEMBRANE TRANSPORTERS ADVANCED MEDICINE, INC. (US) 1999-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030044845-A1 Novel therapeutic agents for membrane transporters SLC47A2, SLC8B1, SLC47A1 NPC1 220/4885RAB9A 1595/4885GRIN1 756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.